
No Label: Geoff Kerchner Dr. Geoff Kerchner, Vice President and Global Head of Neurodegeneration at Roche, Basel, Switzerland, discusses the science behind PrevenTRON, a prevention study evaluating trontinemab in...


science
Hosted by ReachMD · science · EN
Clinical research and advancements furthering clinicians’ ability to diagnose and treat neurological disorders never stop. And neither does NeuroFrontiers, a series dedicated to covering them all. Here neurology specialists will find essential updates on conditions affecting the nervous system, spinal cord, and overall brain health.So if you want to stay up to date on the latest clinical research and news on neurological disorders, then look no further. Because NeuroFrontiers is where neurology specialists and great minds explore the mind itself.
Required Pod Score for this podcast. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
36%
Guest openness
Selective
Sign up to generate a grounded pitch for NeuroFrontiers.
Signup to Generate a PitchClinical research and advancements furthering clinicians’ ability to diagnose and treat neurological disorders never stop. And neither does NeuroFrontiers, a series dedicated to covering them all. Here neurology specialists will find essential updates on conditions affecting the nervous system, spinal cord, and overall brain health.
NeuroFrontiers is hosted by ReachMD. The show has published 187 episodes to date.
Recent episodes include "Can We Delay Alzheimer's Symptoms Before They Begin? Inside the PrevenTRON Trial" (31 August 2026, 9 minutes), "Subcutaneous Lecanemab for Early Alzheimer Disease: Evidence, Safety, and Patient Selection" (20 August 2026, 12 minutes), and "Next-Generation CNS Drug Delivery: Brainshuttle Technology and Clinical Implications in Alzheimer Disease" (17 July 2026, 15 minutes).
NeuroFrontiers publishes roughly every two weeks, with episodes averaging 9 minutes across 187 episodes.
Booking probability for NeuroFrontiers is 36%, and the host is rated Selective on guests. NeuroFrontiers requires a Pod Score of 80 or higher. NeuroFrontiers's contact route on record: verified email.
The strongest fits for NeuroFrontiers are Health & Wellness Services. NeuroFrontiers has a science audience.
ReachMD hosts NeuroFrontiers, a science podcast with 187 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

No Label: Geoff Kerchner Dr. Geoff Kerchner, Vice President and Global Head of Neurodegeneration at Roche, Basel, Switzerland, discusses the science behind PrevenTRON, a prevention study evaluating trontinemab in...

NeuroFrontiers
No Label: Michael Irizarry, MD, MPH Dr. Michael Irizarry, Senior Vice-President, Clinical Research, Eisai, Nutley, NJ, discusses the evidence supporting subcutaneous lecanemab for early Alzheimer disease, including...

NeuroFrontiers
No Label: Luka Kulic, MD In this episode, Luka Kulic, MD, Vice President and Global Head of Early Clinical Development in Neuroscience and Rare Diseases at Roche, Basel, Switzerland, discusses the investigational...

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Zarazuela Zolkipli-Cunningham, MBChB, MRCP Guest: Oscar H. (Hank) Mayer, MD Thymidine kinase 2 deficiency (TK2d) is a rare mitochondrial myopathy that can involve multiple...

NeuroFrontiers
No Label: Michael Levy, MD, PhD No Label: Peter V. Sguigna, MD What do the latest METEOROID trial results mean for neurologists treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)? Michael...

NeuroFrontiers
Guest: Jaime Imitola, MD As stem cell therapies continue to generate significant interest among patients with multiple sclerosis (MS), clinicians must be prepared to distinguish between approved treatments...

Guest: Elizabeth S. Gromisch, PhD Cognitive changes are a common but complex aspect of multiple sclerosis care, making practical and accessible screening strategies essential. In this program, Dr. Elizabeth Gromisch...

Host: Alexandria May, PharmD, BCPS Guest: Kaitlin Batley, MD Fatigue and muscle weakness may seem routine, but when do they signal an underlying condition like thymidine kinase 2 deficiency (TK2d)? To find out, Dr...

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Bethany Lussier, MD Patients often present with respiratory symptoms that don’t quite align with typical pulmonary findings. So what clues should raise our suspicion that...

NeuroFrontiers
Guest: Henry Kaminski, MD Myasthenia gravis is an unpredictable condition, with symptoms and treatment responses that can vary widely from one patient to the next. Tune in to hear Dr. Henry Kaminski explain how to...

NeuroFrontiers
Host: Brian P. McDonough, MD, FAAFP Guest: Austin Larson, MD Emerging research on thymidine kinase 2 deficiency (TK2d) provides new insights into its global genetic prevalence and variability across genetic ancestries...

Guest: Aaron Miller, MD Early real-world experience with the 2024 McDonald criteria suggests a meaningful increase in multiple sclerosis (MS) diagnoses, driven largely by recognition of optic nerve involvement and...

Guest: Raphael Schneider, MD, PhD, FRCPC, CIP Multiplex proteomic biomarker panels are redefining how we understand and monitor multiple sclerosis (MS) by capturing interconnected pathways in a single sample. Hear from...

Guest: Jennifer Yang, MD Emerging evidence shows that children with multiple sclerosis exhibit accelerated biological aging. Learn more about the potential implications with Dr. Jennifer Yang, who spoke about this topic...

Guest: Adil Harroud, MD Guest: Dylan Hamitouche Host: Ryan Quigley Multimodal aging signatures are reshaping our understanding of progression and prognosis in multiple sclerosis (MS). Host Ryan Quigley sits down with...

Host: Jerome Lisk, MD, MBA, M.S., FAAN Guest: Michael Salvatore, PhD Guest: Vicki Nejtek-Salvatore, PhD Translational research is reshaping the way we understand, detect, and manage Parkinson’s disease. To learn more...

Guest: Ashvini Keshavan, MRCP, PhD Very few patients in UK memory services receive an Alzheimer’s diagnosis supported by molecular testing, limiting timely access to emerging therapies. The ADAPT trial—which was funded...

Guest: Sergio Baranzini, PhD In a landmark study involving over 10,000 patients, the International MS Genetics Consortium (IMSGC) has identified the first genetic variant associated with disease severity in multiple...

Guest: Michael Levy, MD, PhD Antibody-mediated demyelinating diseases, such as neuromyelitis optica spectrum disorder and MOG antibody disease, differ fundamentally from multiple sclerosis (MS) due to their association...

Guest: Le Hua, MD Diagnosing multiple sclerosis (MS) in older patients presents unique challenges, especially as age-related comorbidities and common neurological findings often mimic MS. Hear from Dr. Le Hua as she...
Recent guests on NeuroFrontiers. Study who booked and why before you pitch.
Senior Fellow in the American Statecraft Program, Carnegie Endowment for International Peace
Research Director, Division of Neuroimmunology and Neuroinfectious Disease; Associate Professor at Harvard Medical School, Digital Health Institute for Transformation
Associate Professor of Neurology and Psychiatry at NYU Grossman School of Medicine, Director of Neurology Service at Bellevue Hospital, NYU school of medicine
neurologist, researcher, and champion for women’s brain health, University of California, San Francisco
PitchCentric classifies NeuroFrontiers under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.

Neurology® Podcast

Neurology @Point of Care Podcasts

Amplifying the Patient Journey

MedEdTalks - Neurology

The Lancet Neurology in conversation with

The FND Society Podcast
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ